United Therapeutics Corp. CEO Martine Rothblatt Unloads 3,833 Shares (UTHR)
United Therapeutics Corp. (NASDAQ:UTHR) CEO Martine Rothblatt sold 3,833 shares of United Therapeutics Corp. stock in a transaction dated Thursday, October 10th. The shares were sold at an average price of $82.58, for a total value of $316,529.14. Following the completion of the transaction, the chief executive officer now directly owns 140 shares of the company’s stock, valued at approximately $11,561. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
United Therapeutics Corp. (NASDAQ:UTHR) traded up 0.38% on Friday, hitting $81.79. The stock had a trading volume of 653,167 shares. United Therapeutics Corp. has a 52 week low of $44.51 and a 52 week high of $85.92. The stock’s 50-day moving average is $77.43 and its 200-day moving average is $69.33. The company has a market cap of $4.083 billion and a price-to-earnings ratio of 14.05.
United Therapeutics Corp. (NASDAQ:UTHR) last announced its earnings results on Thursday, July 25th. The company reported $1.52 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.47 by $0.05. The company had revenue of $280.60 million for the quarter, compared to the consensus estimate of $250.17 million. During the same quarter last year, the company posted $1.34 earnings per share. United Therapeutics Corp.’s revenue was up 24.4% compared to the same quarter last year. On average, analysts predict that United Therapeutics Corp. will post $5.99 earnings per share for the current fiscal year.
UTHR has been the subject of a number of recent research reports. Analysts at Zacks upgraded shares of United Therapeutics Corp. from a “neutral” rating to an “outperform” rating in a research note to investors on Monday. They now have a $103.00 price target on the stock. Separately, analysts at Goldman Sachs Group Inc. raised their price target on shares of United Therapeutics Corp. from $55.00 to $56.00 in a research note to investors on Wednesday, September 18th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and two have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $66.40.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.